PATENT CLAIM ANALYSIS

Application Number: 16068260
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-01
Patent Classification: ["514", "001100"]

Abstract:
Methods of treating or reducing the risk of developing hidden hearing loss by administering a small molecule Trk agonists (e.g., amitriptyline, imipramine, LM 22A4 (N,N′,N″Tris(2-hydroxyethyl)-1,3,5-benzenetricarboxamide), 7, 8-dihydroxyflavone (DHF), 7,8,3′-Trihydroxyflavone (THF), Mab2256, neurotrophin-4 (NT-4), neurotrophin-3 (NT-3), brain derived neurotrophic factor (BDNF), nerve growth factor (NGF), N-acetylserotonin, N-[2-(5-Hydroxy-1H-indol-3-yl)ethyl]-2-oxo-3-piperidinecarboxamide (HIOC), deoxygedunin, LM-22A4, or tricyclic dimeric peptide 6 (TDP6)).

Claim (Index 9):
The method of  claim 6 , comprising identifying and/or selecting a subject who has hidden hearing loss.

Metadata:
- Claim Count in Document: 26.0
- Percentile: 95.0
- Lexical Diversity: 1.63636
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15796522', '15222710', '14621978', '13877356', '15631933']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7425898205465714
- 35 USC 102 Novelty (BERT): 0.5163058367960505
- Combined Prediction Score: 0.7199614221715194
- Mean Citation Score: 216.365782
- Max Citation Score: 270.39267
- Similarity Product: 175.52150526386262

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test